cemiplimab
sanofi,regeneron
['cemiplimab']
 #hns #oncsurg exciting update phase ii trial of neoadjuvant cemiplimab for advanced, resectable cscc of h&amp;n: 85% pathologic response and 55% complete pathologic response - at median f/u approx 3y, none w/ path response have recurred #asco22 
MD, #melanoma surgical oncologist-investigator at The University of Texas MD Anderson Cancer Center @MDAndersonNews ~ views are my own #endcancer